Xiamen Bensu Pharmaceutical

Xiamen Bensu Pharmaceutical is a clinical-stage biopharmaceutical company based in Xiamen, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on therapeutic areas such as oncology and metabolic diseases, aiming to address significant unmet clinical needs. Its lead candidate, BS-001, is a selective inhibitor currently undergoing clinical trials for hematologic malignancies and solid tumors. Bensu Pharmaceutical leverages its internal R&D capabilities and state-of-the-art facilities to advance its pipeline from early-stage discovery through clinical proof-of-concept. The company is committed to providing high-quality and accessible therapeutic solutions for patients worldwide.